Skip to main content
. 2022 May 16;23(10):5570. doi: 10.3390/ijms23105570

Figure 2.

Figure 2

Representation of the MyD88 and related pathways that can be targeted by specific drugs. Components of the pathways activated by MYD88L265P mutation, such as BTK, IRAKs, and HCK, have proven to be relevant targets for lymphomas. MyD88 is also being used for T-cell immunotherapy as part of CAR T cells, synthetic coreceptors (CD8α:MyD88), or peptides that can induce T-cell responses.